In this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.
The survival benefit associated with high-dose IL-2 in metastatic renal cell carcinoma may be better than previously believed.
Two angiogenesis inhibitors that are widely used in metastatic renal cell carcinoma did not improve survival compared with placebo when used as adjuvant treatment, a new study found.
A novel optical imaging technology is showing promise as a potential diagnostic tool for renal cell carcinoma.
New, large-scale studies on active surveillance, IMRT complications, and robotic versus open prostatectomy were among the highlights of this year’s Genitourinary Cancers Symposium.
Kidney cancer patients were more likely to undergo partial nephrectomy when treated in hospitals that were early adopters of robotic surgery, according to a recent report that one leading expert calls “some of the best evidence to date of a favorable impact of surgical robots in urologic care.”
Monish Aron, MD, presents the take home messages on kidney cancer from the AUA annual meeting in Orlando, FL.
K.C. Balaji, MD, presents the take home messages on basic science research from the AUA annual meeting in Orlando, FL.
Two recently published Mayo Clinic studies provide genetic clues to clear cell renal cell carcinoma that may have important therapeutic implications, researchers say.
None of the comparative studies of robotic radical nephrectomies (RRN) and laparoscopic radical nephrectomies (LRN) has shown benefit of RRN over LRN. Why then are so many minimally invasive RNs performed this way?